Genomic Health, Inc.  

(Public, NASDAQ:GHDX)   Watch this stock  
Find more results for GHDX
+1.12 (3.80%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.70 - 31.24
52 week 24.81 - 33.96
Open 29.80
Vol / Avg. 264,661.00/114,426.00
Mkt cap 1.09B
P/E     -
Div/yield     -
EPS -0.25
Shares 34.34M
Beta 0.44
Inst. own 92%
Jul 31, 2017
Q2 2017 Genomic Health Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 15, 2017
Genomic Health Inc Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
Jun 9, 2017
Genomic Health Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
Jun 6, 2017
Genomic Health Inc at Jefferies Healthcare Conference - 4:30PM EDT - Add to calendar
May 17, 2017
Genomic Health Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 9, 2017
Q1 2017 Genomic Health Inc Earnings Call - Webcast
May 9, 2017
Q1 2017 Genomic Health Inc Earnings Release
Mar 7, 2017
Genomic Health Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -0.96% -4.25%
Operating margin -3.36% -4.71%
EBITD margin - -1.98%
Return on average assets -1.60% -7.22%
Return on average equity -2.04% -9.42%
Employees 846 -
CDP Score - -


301 Penobscot Dr
REDWOOD CITY, CA 94063-4700
United States - Map
+1-650-5569300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Officers and directors

Kimberly J. Popovits Chairman of the Board, President, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon Bradley Cole Chief Financial Officer, Chief Operating Officer, Secretary
Age: 60
Bio & Compensation  - Reuters
Steven Shak M.D. Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 51
Bio & Compensation  - Reuters
Geoffrey M. Parker Director
Age: 51
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Henry J. Fuchs M.D.,Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters